← Leaderboards
Roman Perez-Soler
New York University School Of Medicine
$12,753,063
Attributed
$15,613,887
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$15,613,887 · 7
By mechanism
K12$8,218,171 · 1
R01$6,547,292 · 4
K24$628,100 · 1
R42$220,324 · 1
Top collaborators
- Mark H. Einstein6 shared
- Yiyu Zou6 shared
- Amit Verma1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Harvey Ira Pass$7,723,189
- Leslie S Prichep$1,308,911
- Sean Patrick Heffron$3,853,134
- David L. Stokes$21,994,736
- Jonathan D Newman$4,876,093
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchBaseMalignant NeoplasmsProgramsNonsmall Cell Lung CancerHuman SubjectEpidermal Growth FactorHuman Therapy EvaluationMentorsAlbert Einstein Cancer CenterClinical OncologyInstructionInstitutionGrantK-Series Research Career ProgramsCollegeFundingLeadershipCareerInstitutesAdvisory CommitteesClinical InvestigatorMedicineMember
Grant awards (38)
Paul Calabresi Career Development Award for Clinical Oncology (K12)$774,407
K12 · FY2019 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12)$447,104
K12 · FY2018 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12)$61,698
K12 · FY2018 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12)$810,000
K12 · FY2017 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12)$665,135
K12 · FY2016 · CA · contact PI
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy$442,325
R01 · FY2016 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12)$608,413
K12 · FY2015 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12)$83,374
K12 · FY2015 · CA · contact PI
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy$53,995
R01 · FY2015 · CA · contact PI
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy$483,713
R01 · FY2014 · CA · contact PI
Paul Calabresis Career Development Award For Clinical Oncology$592,932
K12 · FY2013 · CA · contact PI
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy$472,671
R01 · FY2013 · CA · contact PI
Paul Calabresis Career Development Award For Clinical Oncology$1,134,000
K12 · FY2012 · CA · contact PI
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy$402,645
R01 · FY2012 · CA · contact PI
Paul Calabresis Career Development Award For Clinical Oncology$1,133,999
K12 · FY2011 · CA · contact PI
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy$416,169
R01 · FY2011 · CA · contact PI
Paul Calabresis Career Development Award For Clinical Oncology$1,035,496
K12 · FY2010 · CA · contact PI
Paul Calabresis Career Development Award For Clinical Oncology$499,976
K12 · FY2010 · CA · contact PI
Determinants of Resistance to Erlotinib in NSCLC$286,106
R01 · FY2010 · CA · contact PI
Paul Calabresis Career Development Award For Clinical Oncology$371,637
K12 · FY2009 · CA · contact PI
Determinants of Resistance to Erlotinib in NSCLC$286,106
R01 · FY2009 · CA · contact PI
Determinants of Resistance to Erlotinib in NSCLC$286,106
R01 · FY2008 · CA · contact PI
Determinants of Resistance to Erlotinib in NSCLC$286,106
R01 · FY2007 · CA · contact PI
Determinants of Resistance to Erlotinib in NSCLC$294,207
R01 · FY2006 · CA · contact PI
Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer$311,873
R01 · FY2004 · CA
INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER$125,620
K24 · FY2004 · CA
CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS$436,083
R01 · FY2003 · CA
Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer$311,873
R01 · FY2003 · CA
Long-Circulating Liposomal Camptothecins CAP and EAP$220,324
R42 · FY2003 · CA
INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER$125,620
K24 · FY2003 · CA
CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS$423,535
R01 · FY2002 · CA
Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer$311,873
R01 · FY2002 · CA
INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER$125,620
K24 · FY2002 · CA
CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS$358,741
R01 · FY2001 · CA
Chemotherapy and anti EGFR Antibody C225 in Lung Cancer$312,651
R01 · FY2001 · CA
INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER$125,620
K24 · FY2001 · CA
CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS$370,514
R01 · FY2000 · CA
INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER$125,620
K24 · FY2000 · CA